ES2185837T3 - Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion. - Google Patents

Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.

Info

Publication number
ES2185837T3
ES2185837T3 ES97108870T ES97108870T ES2185837T3 ES 2185837 T3 ES2185837 T3 ES 2185837T3 ES 97108870 T ES97108870 T ES 97108870T ES 97108870 T ES97108870 T ES 97108870T ES 2185837 T3 ES2185837 T3 ES 2185837T3
Authority
ES
Spain
Prior art keywords
treatment
theophylin
profilaxis
xantine
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97108870T
Other languages
English (en)
Inventor
Ulrich Dr Gebert
Erhard Dr Wolf
Elisabeth Dr Defossa
Uwe Dr Heinelt
Hiristo Db Anagnostopulos
Karl Dr Rudolphi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19622737A external-priority patent/DE19622737A1/de
Priority claimed from DE1996129815 external-priority patent/DE19629815A1/de
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2185837T3 publication Critical patent/ES2185837T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LAS COMPOSICIONES DE LA FORMULA I SON APTAS COMO MEDICAMENTO PARA EL TRATAMIENTO DE LOS ESTADOS DE SHOCK. LAS COMPOSICIONES DE LA FORMULA VIII SON COMPOSICIONES INTERMEDIAS EN LA FABRICACION DE LAS COMPOSICIONES DE LA FORMULA I.
ES97108870T 1996-06-07 1997-06-03 Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion. Expired - Lifetime ES2185837T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19622737A DE19622737A1 (de) 1996-06-07 1996-06-07 Verwendung von Theophyllinderivaten zur Behandlung und Prophylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE1996129815 DE19629815A1 (de) 1996-07-24 1996-07-24 Verwendung von Theophyllinderivaten zur Behandlung und Prophylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung

Publications (1)

Publication Number Publication Date
ES2185837T3 true ES2185837T3 (es) 2003-05-01

Family

ID=26026372

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97108870T Expired - Lifetime ES2185837T3 (es) 1996-06-07 1997-06-03 Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.

Country Status (26)

Country Link
US (1) US6214992B1 (es)
EP (1) EP0812844B1 (es)
JP (1) JP4156687B2 (es)
KR (1) KR100477177B1 (es)
CN (1) CN1066146C (es)
AR (1) AR007506A1 (es)
AT (1) ATE226583T1 (es)
AU (1) AU712277B2 (es)
BR (1) BR9703499A (es)
CA (1) CA2207120C (es)
CZ (1) CZ292205B6 (es)
DE (1) DE59708533D1 (es)
DK (1) DK0812844T3 (es)
ES (1) ES2185837T3 (es)
HU (2) HU224958B1 (es)
ID (1) ID19469A (es)
IL (1) IL120997A (es)
MX (1) MX9704203A (es)
MY (1) MY117910A (es)
NO (1) NO312400B1 (es)
NZ (1) NZ328017A (es)
PL (1) PL186576B1 (es)
PT (1) PT812844E (es)
RU (1) RU2201930C2 (es)
SI (1) SI0812844T1 (es)
TW (1) TW520285B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
FR2804958B1 (fr) * 2000-02-15 2005-07-08 Hoechst Marion Roussel Inc Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
FR2804867B1 (fr) * 2000-02-15 2002-09-20 Hoechst Marion Roussel Inc Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
DE60307628T2 (de) * 2002-05-31 2007-08-09 Schering Corporation Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen
SI1509525T1 (sl) * 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
CN112500413B (zh) * 2020-10-13 2024-03-01 安徽中医药大学 一类黄嘌呤芳酸醚衍生物，其制备方法及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769377A (en) * 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
US4735898A (en) 1985-07-16 1988-04-05 The University Of Virginia Alumini Patents Foundation Monoclonal antibodies and method of identifying species using the same
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
US4904472A (en) * 1987-04-10 1990-02-27 The University Of Virginia Alumni Patent Foundation Use of adenosine antagonists in the treatment of bradyarrhythmias and mechanical dysfunction associated with cardiopulmonary resuscitation
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
JPH03167186A (ja) * 1989-11-24 1991-07-19 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びその用途
US5036683A (en) * 1990-06-04 1991-08-06 Geuvjehizian Moushegh Y Steering wheel lock protector
DE4019571A1 (de) * 1990-06-20 1992-01-02 Hoechst Ag Pharmazeutische kombinationspraeparate enthaltend cephalosporin- und xanthinderivate und deren verwendung
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
DE59708533D1 (de) 2002-11-28
US6214992B1 (en) 2001-04-10
EP0812844A3 (de) 1998-04-08
RU2201930C2 (ru) 2003-04-10
IL120997A (en) 2001-06-14
HUP9701016A2 (hu) 1998-12-28
MX9704203A (es) 1998-04-30
HU224958B1 (en) 2006-04-28
DK0812844T3 (da) 2003-02-17
EP0812844A2 (de) 1997-12-17
EP0812844B1 (de) 2002-10-23
HU225040B1 (en) 2006-05-29
NZ328017A (en) 2001-05-25
IL120997A0 (en) 1997-11-20
PL186576B1 (pl) 2004-01-30
SI0812844T1 (en) 2003-02-28
HU0500865D0 (en) 2005-11-28
PT812844E (pt) 2003-03-31
CZ292205B6 (cs) 2003-08-13
MY117910A (en) 2004-08-30
AU712277B2 (en) 1999-11-04
CN1169993A (zh) 1998-01-14
TW520285B (en) 2003-02-11
CN1066146C (zh) 2001-05-23
NO312400B1 (no) 2002-05-06
KR980008230A (ko) 1998-04-30
HU9701016D0 (en) 1997-07-28
NO972582D0 (no) 1997-06-06
AU2469897A (en) 1997-12-11
ID19469A (id) 1998-07-16
KR100477177B1 (ko) 2005-09-30
HUP9701016A3 (en) 2004-11-29
NO972582L (no) 1997-12-08
PL320413A1 (en) 1997-12-08
CA2207120C (en) 2007-05-08
JP4156687B2 (ja) 2008-09-24
JPH1059969A (ja) 1998-03-03
CA2207120A1 (en) 1997-12-07
AR007506A1 (es) 1999-11-10
BR9703499A (pt) 1998-10-06
CZ174397A3 (en) 1997-12-17
ATE226583T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
CR7718A (es) Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso
SV1999000009A (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol ref. pg3388/sv
ES2161290T3 (es) Derivados de quinazolina.
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
AR003220A1 (es) Derivados acilados de melatonina; composicion farmaceutica y cosmetica y el uso de los mismos para la preparacion de un medicamento.
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
ES2178779T3 (es) Nuevas amidas de acidos de piridil alcanos como agentes citoestaticos e inmunosupresores.
AR006119A1 (es) Compuestos de quinoxalinadionas uso de los mismos para la fabricacion de un medicamento, compuestos de quinoxalinas para producirlos y procedimiento parala preparacion de los mismos
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2172937T3 (es) 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
AR004480A1 (es) Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
ES2185837T3 (es) Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de las enfermedades de choque, nuevos compuestos de xantina y procedimientos para su produccion.
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
MX9700807A (es) Derivados de 3-azabiciclo (3.2.0)heptano n-sustituidos utiles como neurolepticos.
AR001813A1 (es) Derivados de cromona procedimiento para prepararlos y las composiciones farmacéutica que los contienen
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos